CLINICAL_TRIALS
trial_result
· 2013-09-06
Clinical Trial Update: Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. [Phase 2]
Summary
A Phase 2 trial evaluating BAY 86-9766 in combination with sorafenib for hepatocellular carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED